Business Context and Reporting Period
Filing identity: The provided filing is Neuralstem, Inc.’s unaudited Form 10-Q for the quarter ended March 31, 2013, not Palisade Bio, Inc. Investors should verify the company and filing metadata before relying on this summary.
Neuralstem is a development-stage biotechnology company focused on human neuronal stem-cell therapies and small-molecule compounds for central nervous system diseases. Its lead programs included NSI-566 for ALS, chronic spinal cord injury and ischemic stroke, and NSI-189 for major depressive disorder. The company had 68,797,964 common shares outstanding as of April 30, 2013.
Financial Metrics
| Metric | Three Months Ended March 31, 2013 | Three Months Ended March 31, 2012 |
|---|---|---|
| Revenue | $102,500 | $156,250 |
| Research and development expense | $1,748,347 | $1,422,364 |
| General and administrative expense | $1,195,840 | $1,162,156 |
| Total operating expenses | $2,994,280 | $2,619,466 |
| Operating loss | $(2,891,780) | $(2,463,216) |
| Net loss | $(3,590,087) | $(2,452,781) |
| Net loss per share | $(0.05) | $(0.05) |
| Net cash used in operating activities | $(2,512,728) | $(2,100,610) |
| Cash and cash equivalents at period end | $12,659,240 | $5,144,136 |
Revenue consisted primarily of approximately $103,000 from licensing intellectual property; the company generated no product-sale revenue. Operating expenses were approximately 29 times revenue, and operating and net margins were deeply negative. The filing does not present a meaningful gross margin because the company had no commercial product sales.
At March 31, 2013, total assets were $15.4 million, total liabilities were $9.7 million, stockholders’ equity was $5.7 million, and accumulated deficit was $112.2 million. Cash increased from $7.4 million at December 31, 2012, primarily due to financing proceeds.
In March 2013, the company entered into an $8 million term loan, with potential additional borrowing capacity of $2 million subject to partnership-related conditions. The loan bears variable interest based on prime with an 11% floor, is secured by substantially all assets including intellectual property, and matures in June 2016. Net proceeds were approximately $7.55 million. Interest-only payments run through December 2013, after which principal and interest payments begin.
Material Changes Versus the Prior Comparable Period
- Revenue declined 34% to $102,500 from $156,250, reflecting the end of the Department of Defense subcontract that generated the prior-year revenue.
- Research and development expense increased 23% to $1.75 million, primarily due to higher clinical-trial and laboratory activity, personnel costs, travel and stock-based compensation.
- Total operating expenses increased 14% to $2.99 million.
- Net loss increased 46% to $3.59 million, partly because 2013 included $666,736 of warrant modification expense and $48,257 of interest expense.
- Cash used in operations increased 20% to $2.51 million as clinical and research activities expanded.
- Financing cash inflows increased to $7.83 million from $4.92 million, driven primarily by the March 2013 debt financing rather than an equity offering.
- Common shares outstanding increased from 68.19 million at December 31, 2012 to 68.80 million at March 31, 2013. Significant additional dilution risk existed from outstanding options, warrants and reserved shares.
Guidance, Outlook, Commentary, Risks and Unusual Items
- Management estimated monthly operating cash burn of approximately $890,000 and expected available cash, anticipated income and expected securities proceeds to fund current activities at least through March 31, 2014, although activities and personnel could be reduced.
- The company expected research and development spending to increase as it entered anticipated Phase II and other clinical trials. Management did not expect profitability in the next several years.
- FDA approval to begin the NSI-566 ALS Phase II trial was received in April 2013, with commencement anticipated in the second quarter of 2013. A Phase I chronic spinal cord injury trial and an ischemic-stroke trial in China were also expected to begin in 2013.
- For NSI-189, the final cohort of the Phase Ib major-depression trial was approved in April 2013, with final data expected in September 2013. The company was seeking a development partner after the Phase Ib trial.
- Clinical-stage programs remained subject to substantial safety, efficacy, regulatory, manufacturing and enrollment uncertainty. Positive early-stage or preclinical results were not predictive of later-stage success.
- The company relied heavily on third-party manufacturers, clinical research organizations and other contractors, including Charles River Laboratories for stem cells and AMRI for small-molecule manufacturing.
- The company faced ongoing patent litigation with StemCells, Inc. The ultimate outcome and timing were unknown; management believed ordinary litigation would not materially affect financial condition, results or cash flows.
- The March 2013 financing generated derivative warrant liabilities of $445,680 and included warrants, common shares and financing fees. Warrant modification expense of $666,736 was a material nonrecurring or unusual period item.
- Management stated that additional capital would be required to sustain development efforts. Approximately $28.8 million remained available under the company’s effective shelf registration statement, but future financing might not be available or might be available only on unfavorable terms.
Most Important Facts for Investors to Verify
- Confirm that the filing belongs to Neuralstem, Inc., because the request metadata identifies Palisade Bio, Inc.
- Verify the terms, covenants, collateral and repayment schedule of the $8 million secured term loan and the availability conditions for the additional $2 million.
- Assess cash runway against the reported $890,000 monthly operating burn, planned clinical-trial expansion and expected financing needs.
- Review the extent of potential dilution from approximately 39.9 million shares reserved for equity awards and outstanding options and warrants.
- Verify subsequent clinical-trial progress, enrollment, safety findings and regulatory status for NSI-566 and NSI-189.
- Monitor the StemCells patent litigation and any potential intellectual-property licensing or infringement exposure.
- Evaluate whether licensing revenue is recurring and sustainable, given the absence of commercial product revenue.
- Review the company’s reliance on third-party manufacturers and clinical contractors, as well as its ability to obtain future financing.